Erratum: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
- PMID: 39937959
- DOI: 10.1097/HEP.0000000000001186
Erratum: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Erratum for
-
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18. Hepatology. 2025. PMID: 39422487 No abstract available.
References
REFERENCE
-
- Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81:312–320. doi:10.1097/HEP.0000000000001112. Epub ahead of print. - DOI
Publication types
LinkOut - more resources
Full Text Sources